Status:
UNKNOWN
Survey on the Clinical Use of Recombinant Human Erythropoietin in VLBW and ELBW Infants
Lead Sponsor:
Shenzhen People's Hospital
Conditions:
Erythropoietin; Infant; Surveys and Questionnaires
Eligibility:
All Genders
Brief Summary
Recombinant human erythropoietin (rhEPO) has been shown to effectively and safely prevent the anemia of prematurity and to reduce the transfusion need in very low birth weight (VLBW) and extremly low ...
Detailed Description
The survey was developed by a team of neonatologists at Shenzhen People's hospital . The survey consisted of 26 questions covering three areas: the characteristics of the survey respondents, the use o...
Eligibility Criteria
Inclusion
- neonatologists and pediatricians from general hospitals, maternity and infant hospitals, and children's hospitals across China
Exclusion
- neonatologists and pediatricians from same hospitals
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05372211
Start Date
June 1 2022
End Date
October 1 2022
Last Update
May 12 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.